Skip to content

Spyre Therapeutics, Inc. SYRE Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$69.01M-54.1%-$62.53M-11.1%-$11.18M+83.8%-$36.72M+5.5%-$44.77M-2.1%
$12.81M+44.6%$9.81M+6.5%$9.57M-27.0%$9.38M+7.8%$8.86M-36.0%
-$57.37M-40.0%-$44.58M-19.8%-$37.12M-26.2%-$46.56M+25.2%-$40.99M-43.6%
$56.58M+92,856%-$247.41M-45.1%$25M$79M+166%-$61K+99.9%
$12.26M+9,704%$312.81M+38.7%-$4.64M-136%$731K+103%$125K-99.9%
$11.46M+128%-$16.76M-$40.93M-206%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Spyre Therapeutics, Inc. generate?
Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
Where does Spyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.